1 / 34

Diseases of the Pulmonary Circulation

Diseases of the Pulmonary Circulation. J.B. Handler, M.D. University of New England Physician Assistant Program. PE- pulmonary embolus DVT- deep vein thrombophlebitis CO- cardiac output HF- heart failure OCP- oral contraceptive pill PAP- pulmonary artery pressure

branxton
Télécharger la présentation

Diseases of the Pulmonary Circulation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diseases of the Pulmonary Circulation J.B. Handler, M.D. University of New England Physician Assistant Program

  2. PE- pulmonary embolus DVT- deep vein thrombophlebitis CO- cardiac output HF- heart failure OCP- oral contraceptive pill PAP- pulmonary artery pressure V/Q- ventilation/perfusion CVP- central venous pressure RR- respiratory rate P2- pulmonic valve component of the 2nd heart sound (S2) Vit-vitamin Dx- diagnosis INR- international normalized ratio S4- abnormal 4th heart sound NSST-T- non specific ST-T wave changes ST- sinus tachycardia ABG- arterial blood gas PuVR- pulmonary vascular resistance PPH- primary pulmonary hypertension RAE- right atrial enlargement RVE- right ventricular enlargement S2- second heart sound Rx- treatment PTT- partial thromboplastin time Abbreviations

  3. Pulmonary Thromboembolism • Embolization of thrombus from the venous system into the pulmonary arterial circulation; common, serious and life threatening • 200,000 annual mortality in USA • 3rd leading cause of in-hospital deaths • Majority of deaths from PE unrecognized until post-mortem • 5-7% mortality rate of diagnosed cases with a 40-50% mortality rate of undiagnosed cases

  4. Pulmonary Embolism • The presence of DVT should always sound an alarm. Prior DVT or PE carry a substantial risk for subsequent PE. • Symptoms: Often very difficult to recognize as symptoms are not specific to PE. • 97% of patients with PE will have at least one of the following: tachypnea, dyspnea, pleuritic chest pain (infers infarction). About 1/3 of patients will have tachycardia.

  5. DVT Images.google.com

  6. Pulmonary Thromboembolism • DVT is the most common site of development of thrombus. Usually popliteal and/or iliofemoral vein involvement with subsequent embolization (50-60%) to the pulmonary circulation. • Calf involvement alone carries much less risk of significant embolism. • Calf vein propagation to popliteal and iliofemoral veins occurs in 20% of patients with initial calf involvement. • Pelvic vein thrombosis also common source. • 50% cases of PE lack characteristic symptoms; essential to have high index of suspicion.

  7. Risk Factors for DVT • Venous stasis: Immobility, post-op (large operations, orthopedic procedures), post stroke. • Increased CVP: Decreased CO, CHF, pregnancy. • Hypercoagulability: Meds (OCP), diseases (malignancy), and inherited- several forms: • Factor V Leiden: A hereditary hypercoagulability disorder; common (3% heterozygous incidence) in healthy adults. 20-30% of patients with DVT have this disorder. • Factor V Leiden: Modified clotting factor V, resists degradation by activated Protein Ccoagulation.

  8. Intracardiac Pressures 4-12 4-12 4-12 4-12 4-12 4-12 Images.google.com

  9. Pathophysiology • Obstruction to pulmonary vascular bed by thrombus. • Vasoconstriction develops in the pulmonary arteriolar bed (PuVR) as a result of: • Neurohumoral reflexes, hypoxia, and tissue injury • Result isPAP. • PAPRt heart strain  CO (RVH if PAP s over time)  RV failure: CorPulmonale. • Impaired gas exchange: alveolar dead spacefrom vascular obstruction.

  10. Pathophysiology • physiologic dead space, CO, hypoxemia and surfactant depletion result in atelectasis. • Atelectasis contributes to shunting (below). • Right to left shunting plays a small role: • Atelectasis. • Large PE: Redirection of blood flow into “normal” lung but if inadequate alveolar reserveshunting. • Loss of surfactant, edema and hemorrhage lead to decreased pulmonary compliance, work of breathing.

  11. Ventilation/Perfusion Images.google.com

  12. Symptoms • Dependent on number/size of the emboli and pre-existing pulmonary status. • Constellation of findings: dyspnea, pleuritic (inspiratory) chest pain and tachypnea are predominant symptoms/signs; others include palpitations, wheezing and hemoptysis. • Note: must have high index of suspicion in order to make Dx in many patients.

  13. Signs • Signs: Increased RR, tachycardia, crackles, S4 gallop, decreased S2 splitting with increased P2; friction rubs and cyanosis less common. • Clinical findings of DVT present in only 30-40% of patients with PE but 60-70% will have evidence of DVT by non-invasive imaging (see below).

  14. Investigational Findings • ECG changes common: ST, NSST-T changes. • ABG: Respiratory alkalosis, decreased PO2. • Plasma D-dimer: (>300-500ng/ml) a degradation product of cross-linked fibrin- usually elevated in presence of thrombus (97% sensitivity), but not specific (45%). Commonly combined with other diagnostic studies (CT angiography)predicts likelihood of PE. • CxR: often abnormal- atelectasis, pleural effusions, pleural based infiltrates; necessary to exclude other pulmonary pathology.

  15. Images.google.com

  16. V/Q Lung Scan • Radioisotopes used to image ventilation and perfusion. Defects develop in areas of lung that remain ventilated without perfusion; inaccurate in presence of other pulmonary pathology. • Graded low (normal), intermediate and high probability for PE. • Supplanted as diagnostic test by Helical CT angiography (below).

  17. Pulmonary Circulation Imaging • Helical (spiral) CT Angiography: Sensitive for proximal vessel thromboembolism; overall 83% sensitive, >90% specific; alternative to V/Q scanning as a screening procedure. More often done compared to V/Q. • Pulmonary angiography: reference standard for the Dx of PE- Invasive with 5% complication rate (contrast reaction, renal failure, arrhythmias) high sensitivity, specifity. Indicated when V/Q or CT scans are indeterminate, DVT studies are negative, and PE still suspected clinically.

  18. Helical CT: Pulmonary Embolus

  19. Pulmonary Angiography

  20. DVT Studies • If Dx is uncertain and DVT is proven, likely that PE is present if clinically suspected. • Venous ultrasound with doppler: Non- invasive test of choice for DVT. • Contrast Venography: “reference standard”-highly accurate and invasive, has been replaced by ultrasound which is non-invasive and easier to perform.

  21. Clinical feature Points Clinical symptoms of DVT 3 Other diagnosis less likely than PE 3 Heart rate greater than 100 beats per minute 1.5 Immobilization or surgery within past 4 weeks 1.5 Previous DVT or PE 1.5 Hemoptysis 1 Malignancy 1 Total points Integrated Approach for Dx of PE: Clinical Features + Diagnostic Testing Wells et. al

  22. Clinical Probability of PE PE Unlikely PE Likely D-dimer assay Helical CT-PA Negative Positive Normal Findings of PE PE Excluded Rx for PE PE excluded - study Indeterminate Current fig 9-1 LE US or Pulm angiogram + study

  23. Treatment of 1st PE • Full anticoagulation for minimum 6 months or longer depending on risk factors for recurrence. • Unfractionated heparin: Binds to and potentiates antithrombin III inactivates clotting factors IXa, Xa, XIa, XIIa; retards additional thrombus formation. • Administered by continuous IV infusion and requires frequent monitoring (highly protein bound) of PTT for dose adjustment; for 5-7 days. • Wt. Based dosing: 80U/kg loading dose, then 18U/kg/hrgoal PTT 1.5-2.5x control (46-70 sec) • Risks: Bleeding, thrombocytopenia.

  24. Low Molecular Weight Heparin: depolymerized heparin, less protein and cellular bound, increased bioavailability; also given for 7 days. More predictive dose response, as/more effective than unfractionated heparin. Decreased risk of hemorrhage and thrombocytopenia; 1-2x daily dosing (weight based) without need for lab testing. • Warfarin- oral anticoagulant, blocks action of Vit K, inhibiting hepatic synthesis of Vit K dependent clotting factors (II, VII, IX, X). Initiated over 5-7 days (with patient on heparin) and continued for desired period of time. Goal: INR (adjusted PT) of 2-3.

  25. Thrombolytic Therapy • Streptokinase, Urokinase and t-PA: directly lyse intravascular thrombi and accelerate resolution of emboli within 1st 24 hours compared to standard heparin therapy, but do not decrease mortality. • Indications: patients with massive PE at high risk of death (unstable on heparin). • Contraindications: active internal bleeding, stroke in prior two months, surgery or trauma in prior 6 weeks and uncontrolled hypertension.

  26. Surgical Interventions • Mechanical or surgical thrombus extraction- last resort in a dying patient. • Vena caval interruption: Indicated in patients with DVT/PE that cannot be anticoagulated or recurrent PE while already fully anticoagulated. Vena caval filter/umbrella can be introduced percutaneously via internal jugular vein. • Prognosis of PE if diagnosed: < 3% incidence of death from recurrent PE if initial event is recognized and adequately treated.

  27. Prevention of PE • Identify patients at high risk for DVT: lengthy hospitalization/immobilization, orthopedic surgery, esp. hip repair (incidence of DVT 10-20% if untreated with prophylactic anticoagulation and other measures). • Strategies for prevention:-early ambulation-elastic stockings-mechanical compression devices-anticoagulation.

  28. Pharmacologic Prophylaxis • Patients with high risk for DVT and PE • Low doses (below full anticoagulation dose) of anticoagulants (’s risk of bleeding) decreases incidence of DVT/PE: Unfractionated Heparin Low molecular weight (LMW) heparin • Sometimes continued as OP (warfarin/coumadin) in patient likely to remain immobile.

  29. Pulmonary Hypertension • Pulmonary circulation is a low pressure system with high blood flow and low PuVR (200 resistance units compared with 800-1000 RU for the systemic circulation. • In a variety of disease states (e.g. PE) there is constriction of smooth muscle in the walls of pulmonary arteriolar resistance vessels. • Pulmonary Hypertension is present when the PAP rises to a high level, inappropriate for a given level of cardiac output. • PPH- rare idiopathic disorder in woman.

  30. Idiopathic (Primary) Pulmonary Hypertension • No other underlying cardiopulmonary disease: An arteriopathy. Medial hypertrophy, fibrosis and recanalized thrombi are common pathology findings; poor prognosis- mean survival post Dx is 2-5 years. • Marked PuVR and PAP. • Association: anorexigens, collagen-vascular disease. • Fenflouramine appetite suppressants: Marked recent in PPH (U.S. and Europe); similar events in 1960’s with Amrinox. Both taken off market.

  31. Secondary Pulmonary HTN • Reduction of x-sectional area of the pulmonary vascular bed: • Vasoconstriction: Hypoxia from any cause (most important and potent stimulus), lactic acidosis. • Loss of vessels: Vasculitis, emphysema, interstitial dis. • Obstruction of vessels: Multiple or recurrent PE. • Chronically increased pulmonary venous pressure (HF, mitral stenosis). • pulmonary blood flow: Congenital Ht Disease. • Once present, secondary structural changes occur resulting in further destruction of vessels.

  32. Signs and Symptoms • Dyspnea- initially exertional, then rest. • Retrosternal chest pain (mimics angina); fatigue and syncope result from decreased CO. • Physical Exam: Narrowly split or single S2, P2. • CxR: Dilated main PA with “pruning” of vessels. • Echo-Doppler: best non-invasive tool: RAE, RVE; elevated PA and RV systolic pressure. • Right heart cath: precise measurement of right heart pressures essential to Dx and Rx.

  33. Treatment • Treat underlying disease process if present. • Supplemental chronic O2 if hypoxemic. • Full anticoagulation: PPH only • Prostacyline (Epoprostenol, Treprostinil): via continuous IV infusion potent pulmonary vasodilator; symptoms and mortality.

  34. Treatment • Bosentan (Tracleer): new oral endothelin-1 receptor antagonist for chronic PAH; symptoms. • Sildenafil: inhibits phosphodiesterase type 5; pulmonary vasodilator- improves symptoms. • Lung or heart/lung transplant: 50-65% 2 year survival. Better long term survival with bilateral (vs. unilateral) lung transplant.

More Related